The results of the VOLGA trial have buoyed AstraZeneca’s ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844